Vincent El Ghouzzi

Dr. Vincent El Ghouzzi

Université de Paris, NeuroDiderot, INSERM, Paris, France
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1997 in Nature Genetics
Verified
Journal Article
Closed access
Vincent El GhouzziVincent El Ghouzzi
Vincent El Ghouzzi
MMMartine Le Merrer
Martine Le Merrer
FPFabienne Perrin-Schmitt
Fabienne Perrin-Schmitt
ELElisabeth Lajeunie
Elisabeth Lajeunie
PBPaule Benit
Paule Benit
JBJacky Bonaventure
Jacky Bonaventure

1 April 1996 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
FRF. Rousseau
F. Rousseau
Vincent El GhouzziVincent El Ghouzzi
Vincent El Ghouzzi
ADA. L. Delezoide
A. L. Delezoide
LLL. Legeai-Mallet
L. Legeai-Mallet
MMM. Le Merrer
M. Le Merrer
JBJ. Bonaventure
J. Bonaventure
Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced thoracic cavity. In the most common subtype (TD1), femurs are curved, while in TD2, straight femurs are associated with cloverleaf skull. Mutations in the fibroblast growth factor receptor 3 (FGFR3) gene were identified in both subtypes. While TD2 was accounted for by a single recurrent mutation in the tyrosine kinase 2 domain, TD1 resulted from either stop codon mutations or missense mutations in the extracellular domain of the gene. Here, we report the identification of FGFR3 mutations in 25/26 TD cases. Two novel missense mutations (Y373C and G370C) were detected in 8/26 and 1/26 TD1 cases respectively. Both mutations created cysteine residues in the juxta extramembrane domain of the receptor. Sixteen cases carried the previously reported R248C (9/26 cases), S249C (2/26 cases) or stop codon FGFR3 mutations (5/26 cases). Our results suggest that TD1 is a genetically homogeneous condition and give additional support to the view that newly created cysteine residues in the extracellular domain of the protein play a key role in the severity of the disease.

29 September 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JBJean-Jacques Brière
Jean-Jacques Brière
JFJudith Favier
Judith Favier
PBPaule Bénit
Paule Bénit
Vincent El GhouzziVincent El Ghouzzi
Vincent El Ghouzzi
ALAnnalisa Lorenzato
Annalisa Lorenzato
PRPierre Rustin
Pierre Rustin
The genes encoding succinate dehydrogenase (SDH) subunits B, C and D, act as tumour suppressors in neuro-endocrine tissues. Tumour formation has been associated with succinate accumulation. In paraganglioma cells, two forms of SDHA (type I, II) were found which might preclude significant succinate accumulation in the case of a mutation in either form. In fibroblasts only SDHA type I is found. In these cells, SDHA type I mutation leads to SDH deficiency, succinate accumulation and hypoxia-inducible factor 1α(HIF1α) nuclear translocation. HIF1α nuclear translocation was not observed in ATPase-deficient fibroblasts with increased superoxide production and was found to be independent of cellular iron availability in SDHA-mutant cells. This suggests that neither superoxides nor iron were causative of HIF1α nuclear translocation. Conversely, α-ketoglutarate (α-KG) inhibits this nuclear translocation. Therefore, the pseudo-hypoxia pathway in SDH-deficient cells depends on the HIF1αprolyl hydroxylase product/substrate (succinate/α-KG) equilibrium. In SDH deficiency, organic acids thus appear instrumental in the HIF1α-dependent cascade suggesting a direct link between SDH and tumourigenesis.

1 November 2011 in Annals of Neurology
Verified
Journal Article
Closed access
LTLuigi Titomanlio
Luigi Titomanlio
AKAnnemieke Kavelaars
Annemieke Kavelaars
JDJeremie Dalous
Jeremie Dalous
SMShyamala Mani
Shyamala Mani
Vincent El GhouzziVincent El Ghouzzi
Vincent El Ghouzzi
PGPierre Gressens
Pierre Gressens

18 January 2006 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
ELElisabeth Lajeunie
Elisabeth Lajeunie
SHSolange Heuertz
Solange Heuertz
Vincent El GhouzziVincent El Ghouzzi
Vincent El Ghouzzi
JMJelena Martinovic
Jelena Martinovic
DRDominique Renier
Dominique Renier
JBJacky Bonaventure
Jacky Bonaventure

1 March 1999 in Journal of Neurosurgery
Verified
Journal Article
Closed access
ELElisabeth Lajeunie
Elisabeth Lajeunie
RCRhoda Cameron
Rhoda Cameron
Vincent El GhouzziVincent El Ghouzzi
Vincent El Ghouzzi
NPNathalie de Parseval
Nathalie de Parseval
PJPierre Journeau
Pierre Journeau
DRDominique Renier
Dominique Renier
Object. Apert's syndrome is characterized by faciocraniosynostosis and severe bony and cutaneous syndactyly of all four limbs. The molecular basis for this syndrome appears remarkably specific: two adjacent amino acid substitutions (either S252W or P253R) occurring in the linking region between the second and third immunoglobulin domains of the fibroblast growth factor receptor (FGFR)2 gene. The goal of this study was to examine the phenotype/genotype correlations in patients with Apert's syndrome.Methods. In the present study, 36 patients with Apert's syndrome were screened for genetic mutations. Mutations were detected in all cases. In one of the patients there was a rare mutation consisting of a double—base pair substitution in the same codon (S252F). A phenotypical survey of our cases was performed and showed the clinical variability of this syndrome. In two patients there was no clinical or radiological evidence of craniosynostosis. In two other patients with atypical forms of syndactyly and cranial abnormalities, the detection of a specific mutation was helpful in making the diagnosis.Conclusions. The P253R mutation appears to be associated with the more severe forms, with regard to the forms of syndactyly and to mental outcome. The fact that mutations found in patients with Apert's syndrome are usually confined to a specific region of the FGFR2 exon IIIa may be useful in making the diagnosis and allowing genetic counseling in difficult cases.